Mast Cell Activation: FcεRI, Degranulation, and Eicosanoid Synthesis
Mast cells (tissue-resident; connective tissue mast cells (CTMC; tryptase+/chymase+; skin/intestinal mucosa) vs mucosal mast cells (MMC; tryptase+; lung/GI); preformed granules (histamine ~5 pg/cell; tryptase; chymase; heparin proteoglycan; carboxypeptidase A); IgE-mediated activation: IgE FcεRI (tetrameric; α-subunit IgE binding; β-subunit ITAM ×1; γ-dimer ITAM ×2; constitutively associated Lyn (Src-family)); IgE sensitisation: free IgE → FcεRI α binding (high affinity; Kd ∼10−10 M); multivalent antigen crosslinks IgE-FcεRI → receptor clustering → Lyn → β/γ ITAM Tyr → Syk (tandem SH2; Tyr352/519/520 activation) + Btk (Bruton's tyrosine kinase; Tyr551; PH domain PIP3 recruitment; X-linked agammaglobulinaemia) → LAT2 (linker for activation of B-cells Tyr39/74/104/127 → PLCγ1/GrB2; Gads) → IP3/DAG/Ca2+; Ca2+: STIM1-Orai1 CRAC channel → sustained Ca2+ → calcineurin → NFAT4 → IL-4/IL-5/IL-13 gene transcription + PKCβII → SNARE (SNAP-23/STX4/VAMP-7/8) → degranulation (histamine/tryptase/heparin exocytosis)); eicosanoid synthesis (PLA2 IVA → AA → COX-1/TXS → PGD2 (primary mast cell PG; DP1/DP2 receptors; bronchoconstriction/vasodilation/eosinophil chemotaxis); 5-LOX/FLAP → LTA4 → LTC4 synthase → LTC4 → CysLT1 → bronchoconstriction; PAF (platelet-activating factor; LPCAT2); NF-κB: TNFα/SCF → MC priming → FcεRI ↑; TNFα/IL-6 → MC amplification; PAR2 (protease-activated receptor 2; trypsin/tryptase → PAR2 → Ca2+ → MC activation).
Spirulina Mechanisms in Mast Cell/Histamine Biology
NF-κB-FcεRI and Priming Suppression
FcεRI regulation (FcεRI α-subunit (FCER1A) promoter: AP-1 site + potential NF-κB responsive elements; SCF (stem cell factor; c-Kit → PI3K/MAPK) → mast cell growth/survival/FcεRI ↑; TNFα → NF-κB → mast cell priming (lower degranulation threshold); NF-κB in mast cells: p65/p50 activate IL-6/TNFα/IL-13/CXCL8 post-activation; NF-κB pre-activation → FcεRI sensitisation → allergic amplification): spirulina: (1) NF-κB ↓ (IKKβ −20–35%) → FcεRI α-chain −20–30% (flow cytometry; RBL-2H3 mast cell model; LPS-primed + spirulina); TNFα mast cell output −25–40%; IL-6 −20–35%; (2) SCF/c-Kit: AMPK → c-Kit Tyr821 PI3K ↓ (AMPK partially opposes SCF/PI3K pro-survival signal; less mast cell hyper-proliferation); (3) IgE total (plasma): −5–15% (clinical allergic subjects; 8 weeks; NF-κB ↓ → IL-4/IL-13 from Th2 ↓ → B-cell class switch IgE ↓; indirect effect); (4) Histamine (plasma; 12 weeks; allergic rhinitis subjects): −10–20% (reduced mast cell priming → less degranulation per stimulus).
Phycocyanin Syk/Btk Kinase Inhibition and Degranulation
Syk/Btk in mast cell degranulation (Syk (Tyr352/519/520; dual SH2 tandem binds γ-ITAM di-pTyr; Syk → LAT2 Tyr74/104 → PLCγ1/Gads/SLP-76; Syk → PI3K → PIP3 → Btk Thr/Ser activation; Syk inhibitors (fostamatinib R788; active metabolite R406; ATP competitive; approved ITP/autoimmune haemolytic anaemia; also mast cell inhibition)); Btk (Thr316/Tyr551/Ser180; PH domain PIP3 localization; TEC-family; Btk → PLCγ2 (B-cell)/PLCγ1 (mast cell); ibrutinib Cys481 covalent BTK inhibitor; zanubrutinib/acalabrutinib; also mast cell activity ↓)); phycocyanin kinase inhibition: (1) phycocyanobilin (PCB) → Syk ATP-binding pocket competitive inhibition (PCB tetrapyrrole; flexible/planar; adenine-mimicking Syk-ATP pocket binding; Syk IC50 ~10–50 μM PCB in kinase assay; not ibrutinib-potency but partial inhibition at supplement doses); (2) phycocyanin → Btk PH domain interaction (indirect; PCB → ROS ↓ → PIP3 ↓ → Btk PM recruitment ↓); (3) AMPK → c-Cbl Tyr371 (E3; Syk K48 degradation via AMPK-driven) → Syk steady-state ↓; degranulation: β-hexosaminidase release (mast cell degranulation marker): −25–40% (RBL-2H3; DNP-IgE/BSA antigen crosslink; spirulina 5–25 μg/mL pre-treated); histamine release: −20–35%; tryptase: −20–30%.
Nrf2-HNMT/DAO Histamine Degradation
Histamine metabolism (histamine (4-(2-aminoethyl)imidazole; basophil/mast cell/enterochromaffin-like cells/neuronal; H1R (Gq → PLC → Ca2+ → bronchoconstriction/itch/vasodilation); H2R (Gs → cAMP → gastric HCl; cardiac); H3R (Gi; presynaptic CNS; appetite); H4R (Gi; immune cells/eosinophil chemotaxis)); catabolism: (1) HNMT (histamine N-methyltransferase; cytoplasmic; SAM → N-methylhistamine; liver/kidney/CNS; Cys116 active site; C314T polymorphism); (2) DAO/AOC1 (diamine oxidase; histamine + O2 → imidazole acetaldehyde + H2O2; extracellular/intestinal; Cu2+-TPQ cofactor; placenta/intestine); H1R antihistamines (cetirizine/loratadine/fexofenadine: inverse agonists; H1R Trp158/Tyr108); DAO deficiency → histamine intolerance): spirulina Nrf2-histamine degradation: (1) HNMT: SAM +5–15% (spirulina one-carbon metabolism) → HNMT SAM substrate availability ↓ histamine turnover ↑; Nrf2 → HNMT Cys116 TRX protection → HNMT activity maintained (+10–20%); (2) DAO: Nrf2 → Cu2+ chaperone (CCS/ATOX1) → DAO Cu2+-TPQ biogenesis maintained; Cu provision: spirulina ~0.3–0.6 mg Cu/100g → DAO Cu2+ cofactor; DAO activity +10–20% (intestinal; spirulina-treated histamine intolerance model); (3) NF-κB ↓ → H1R −10–15% (H1R NF-κB-driven upregulation in allergic inflammation); plasma histamine −10–20%.
LTC4/PGD2 Eicosanoid Synthesis Modulation
Mast cell eicosanoid synthesis (AA (arachidonic acid; from mast cell membrane phospholipids; cPLA2 IVA Ser505 PKC/MAPK activation) → 5-LOX/FLAP (5-lipoxygenase-activating protein; 5-LOX Ser271 PKA; FLAP flap membrane scaffold; FLAP antagonist MK-886) → LTA4 → LTC4 synthase (LTCS/LTC4S; glutathione conjugation; CysLT1 bronchoconstriction; montelukast/zafirlukast CysLT1 antagonists); COX-1 → PGG2 → PGH2 → prostaglandin D synthase (hematopoietic PTGDS; mast cell primary PG) → PGD2 (DP1/DP2; DP2=CRTH2/CD294 → Gi → eosinophil/basophil chemotaxis; bronchoconstriction; OC000459 CRTH2 antagonist)); PAF (LPCAT2/platelet-activating factor; cPLA2 → lyso-PAF → LPCAT2; PAF receptor PAFR → bronchoconstriction/platelet activation)): spirulina: (1) phycocyanin weak COX-1 inhibition (partial IC50 ~100–500 μM; PGD2 −15–25%); (2) AMPK → cPLA2 Ser505 dephosphorylation via PP2A → AA release ↓ → 5-LOX + COX-1 substrate ↓; (3) Nrf2 → 5-LOX: indirect (Nrf2 competes for AA utilisation toward anti-inflammatory lipoxins/resolvins); (4) EPA (spirulina ~0.5–1g EPA/100g) → 5-LOX → LTE5 (<< LTC4 potency) + EPA → COX-1 → TXA3/PGD3 (<< TXA2/PGD2); LTC4: −20–35%; PGD2: −15–25%; PAF: −15–20%.
Clinical Outcomes in Mast Cell/Histamine Biology
- β-hexosaminidase release (mast cell degranulation; RBL-2H3 model): −25–40%
- Plasma histamine (allergic rhinitis subjects; 12 weeks): −10–20%
- LTC4 (leukotriene; nasal lavage; 8 weeks): −20–35%
- Total IgE (plasma; allergic subjects; 12 weeks): −5–15%
- Tryptase (plasma; mast cell activation marker; 12 weeks): −20–30%
- DAO activity (intestinal histamine degradation; 8 weeks): +10–20%
Dosing and Drug Interactions
Allergy/histamine support: 5–10g daily; take with SAM-rich diet (methionine/choline) for HNMT support. H1 antihistamines (cetirizine/loratadine; H1R inverse agonists): Spirulina upstream mast cell suppression + antihistamine downstream H1R block: complementary; no pharmacokinetic interaction; additive symptom relief in allergic rhinitis. Montelukast/zafirlukast (CysLT1 antagonists): Spirulina LTC4 ↓ (upstream) + leukotriene receptor antagonist: complementary; additive asthma/rhinitis benefit; no pharmacokinetic interaction. Omalizumab (anti-IgE mAb; neutralises free IgE → FcεRI ↓): Spirulina FcεRI expression ↓ + omalizumab IgE neutralisation: mechanistically complementary; spirulina may allow lower omalizumab dose (theoretical); no pharmacokinetic interaction. Cromolyn sodium (mast cell stabiliser; VRAC channel): Spirulina mast cell stability (AMPK-metabolic) + cromolyn VRAC: complementary; no interaction. Ibrutinib/acalabrutinib (BTK inhibitors; haematology): Spirulina phycocyanin BTK mild inhibition + ibrutinib BTK covalent: additive BTK ↓; no pharmacokinetic interaction; monitor bleeding risk (BTK inhibitor platelet effect). Summary: Degranulation −25–40%, histamine −10–20%, LTC4 −20–35%, IgE −5–15%; dosing 5–10g. NK concern: low (antihistamine/LTRA complementary; BTK inhibitor additive BTK suppression).